Cargando…

δEF1 Down-Regulates ER-α Expression and Confers Tamoxifen Resistance in Breast Cancer

Resistance to tamoxifen therapy represents a major barrier to the successful treatment of breast cancer, where a loss of or reduced ER-α level is considered a primary mechanism. Understanding how ER-α expression is regulated would provide insights into new intervention points to overcome tamoxifen r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Shaocong, Li, Yaqing, Tong, Qi, Gu, Feng, Zhu, Tianhui, Fu, Li, Yang, Shuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528679/ https://www.ncbi.nlm.nih.gov/pubmed/23285017 http://dx.doi.org/10.1371/journal.pone.0052380

Ejemplares similares

BMP-6 promotes E-cadherin expression through repressing δEF1 in breast cancer cells
por: Yang, Shuang, et al.
Publicado: (2007)

LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
por: Xue, Xingyang, et al.
Publicado: (2015)

COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR
por: Lu, Renquan, et al.
Publicado: (2016)

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022)

circRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells
por: Li, Zheng, et al.
Publicado: (2023)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer
por: Zheng, XQ, et al.
Publicado: (2013)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

Z-ligustilide restores tamoxifen sensitivity of ERα negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERα
por: Ma, Hui, et al.
Publicado: (2017)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021)

Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression
por: Li, Yuanyuan, et al.
Publicado: (2017)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
por: Perez White, Bethany, et al.
Publicado: (2013)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
por: Maselli, Angela, et al.
Publicado: (2019)

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
por: Gao, Ang, et al.
Publicado: (2018)

ER-α36, a Novel Variant of ER-α, Mediates Estrogen-Stimulated Proliferation of Endometrial Carcinoma Cells via the PKCδ/ERK Pathway
por: Tong, Jing-Shan, et al.
Publicado: (2010)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
por: Turczyk, Lukasz, et al.
Publicado: (2017)

Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells
por: Kim, Seung-Su, et al.
Publicado: (2020)

Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer
por: Vafeiadou, Vasiliki, et al.
Publicado: (2022)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer
por: Ye, Runyi, et al.
Publicado: (2021)

Retraction Note to: Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
por: White, Bethany Perez, et al.
Publicado: (2017)

Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells
por: Zhang, Xiumei, et al.
Publicado: (2019)

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
por: Gao, Tian, et al.
Publicado: (2014)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
por: Ouyang, Yan Xiu, et al.
Publicado: (2021)

miR-1271 inhibits ERα expression and confers letrozole resistance in breast cancer
por: Yu, Tao, et al.
Publicado: (2017)

Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression
por: Zhang, Xia, et al.
Publicado: (2015)

Effects of 17β-estradiol and tamoxifen on gastric cancer cell proliferation and apoptosis and ER-α36 expression
por: Wang, Xuming, et al.
Publicado: (2017)

Estrogen receptor variant ER‐α36 promotes tamoxifen agonist activity in glioblastoma cells
por: Qu, Chao, et al.
Publicado: (2019)

FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis
por: Xu, Lu, et al.
Publicado: (2021)

Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36
por: Shen, Yingying, et al.
Publicado: (2018)

Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells
por: Qi, Wenwen, et al.
Publicado: (2016)

Impairment of T Cell Development in δ EF1 Mutant Mice
por: Higashi, Yujiro, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_r9ucuvkt5usajjhfkju5s3dm1i